|
|
Volumn 14, Issue 4, 2016, Pages 373-377
|
|
NCCN guidelines and quality cancer care: Where have we come from, and where should we be going?
a
a
Medical School
*
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BIOLOGICAL MARKER;
INTERFERON;
IPILIMUMAB;
ARTICLE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER CENTER;
CANCER CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER LOCALIZATION;
CANCER MORTALITY;
CANCER PROGNOSIS;
CANCER RECURRENCE;
CANCER RISK;
CANCER SCREENING;
CANCER STAGING;
CLINICAL EFFECTIVENESS;
COMORBIDITY;
CONSENSUS;
DOCTOR PATIENT RELATION;
EDUCATIONAL STATUS;
ESTHETICS;
EVIDENCE BASED PRACTICE;
FOLLOW UP;
HEALTH CARE AVAILABILITY;
HEALTH CARE COST;
HEALTH CARE PLANNING;
HEALTH CARE POLICY;
HEALTH CARE QUALITY;
HEALTH EQUITY;
HEALTH SERVICE;
HUMAN;
INCIDENCE;
MASTECTOMY;
MEDICAID;
MEDICARE;
MELANOMA;
PALLIATIVE THERAPY;
PATIENT ATTITUDE;
PATIENT CARE;
PATIENT PREFERENCE;
PATIENT SAFETY;
PATIENT SATISFACTION;
PRACTICE GUIDELINE;
PREJUDICE;
PROFESSIONAL COMPETENCE;
PROGNOSTIC ASSESSMENT;
PROPHYLACTIC SURGICAL PROCEDURE;
PROTOCOL COMPLIANCE;
QUALITY CANCER CARE;
SENTINEL LYMPH NODE BIOPSY;
STANDARD;
STRESS;
TERMINAL CARE;
TREATMENT DURATION;
NEOPLASMS;
HUMANS;
NEOPLASMS;
PRACTICE GUIDELINES AS TOPIC;
QUALITY OF HEALTH CARE;
|
|
EID: 84964321135
PISSN: 15401405
EISSN: 15401413
Source Type: Journal
DOI: 10.6004/jnccn.2016.0044 Document Type: Article |
|
Times cited : (6)
|
|
References (6)
|
